Chargeback Management

Gain better control of pharmaceutical chargebacks through unparalleled chargeback data processing and analytics

Data retrieval, scrubbing, validation and reconciliation, at scale, is a daunting challenge for most companies, and becomes even more critical for high priced products.

Effective Chargeback Data Management can uncover up to 10-15% gross margin erosion based on the trade partner mix, commercial contract volume, discount levels, and DSA terms

With IntegriChain’s Chargeback Management BPaaS (Business Process as a Service), we offer a full suite of pharmaceutical chargeback data reconciliation and analytics services across Commercial and Government contracts such as GPO/IDN providers, 340B and FSS. Our services marry expert contract management along with unparalleled chargeback verification, uniquely applying the most comprehensive set of validity checks and delivering operational reporting and wholesaler scorecards for more accurate chargeback data management.

Chargeback Management Color Diagram
Chargeback Error Detection

ICyte: Built for Chargeback Management Usability and Productivity

For a number of reasons, pharmaceutical manufacturers regularly are forced to spend system and human resources on identifying and resolving chargeback errors. Clearly, wholesaler distribution faces severe margin pressure. Further, widening gaps between 340B contract price and WAC incentivize arbitrage behavior, and trade partners don’t report chargeback reversals on salable returns to inventory up to 90 days after the original sale. In all cases, chargeback errors are difficult to prove without sophisticated analytics, experienced staff, and a robust application for identification of errors.

ICyte Chargeback Application provides:

  • Validations and HDA Error Processing Reconciliation
  • Resubmission Processing
  • Parent/child Membership Management for Wholesalers and Payers
  • Full EDI 844, 845, and 849 capabilities
  • Wholesaler Scorecards
  • ERP Integration

Interested in learning more?

Streamline your chargeback data.


Perspectives on Pharma Market Access Launch & Challenges: Part 2

Commercialization is a critical process for any pharmaceutical manufacturer, with alignment of multiple work streams that span across market access and brand teams as well as finance and the c-suite. We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.

Read the Blog


May Market Update

Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.

Read the Blog

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article